Abstract
Highly active antiretroviral therapy (HAART) has changed the natural course of HIV infection. However, the toxicities associated with long-term use of nucleoside reverse transcriptase inhibitors (NRTIs) have led to the assessment of dual-therapy approaches with less toxicity. Atazanavir and dolutegravir have antiviral potency, tolerability and favourable metabolic profile. In suppressed HIV-infected patients, with NRTIs-related toxicity effects, the association of atazanavir and dolutegravir, favoured by their positive pharmacokinetics interaction, could be used as ‘maintenance’ antiretroviral therapy. We report a case report about one HIV-infected patient, on HAART and with a persistent suppression of HIV RNA, switched to dolutegravir 50 mg three times weekly plus atazanavir 400 mg once daily, as ‘maintenance antiretroviral therapy’, with persistence of viral suppression.
| Original language | English |
|---|---|
| Pages (from-to) | 726-728 |
| Number of pages | 3 |
| Journal | International Journal of STD and AIDS |
| Volume | 28 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jan 1 2017 |
Fingerprint
Keywords
- Atazanavir
- dolutegravir
- maintenance antiretroviral therapy
- pharmacokinetics
ASJC Scopus subject areas
- Dermatology
- Public Health, Environmental and Occupational Health
- Pharmacology (medical)
- Infectious Diseases
Cite this
Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient. / Lanzafame, Massimiliano; Lattuada, Emanuela; Nicolè, Stefano; Rigo, Fabio; Cucchetto, Giulia; Concia, Ercole; Vento, Sandro.
In: International Journal of STD and AIDS, Vol. 28, No. 7, 01.01.2017, p. 726-728.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient
AU - Lanzafame, Massimiliano
AU - Lattuada, Emanuela
AU - Nicolè, Stefano
AU - Rigo, Fabio
AU - Cucchetto, Giulia
AU - Concia, Ercole
AU - Vento, Sandro
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Highly active antiretroviral therapy (HAART) has changed the natural course of HIV infection. However, the toxicities associated with long-term use of nucleoside reverse transcriptase inhibitors (NRTIs) have led to the assessment of dual-therapy approaches with less toxicity. Atazanavir and dolutegravir have antiviral potency, tolerability and favourable metabolic profile. In suppressed HIV-infected patients, with NRTIs-related toxicity effects, the association of atazanavir and dolutegravir, favoured by their positive pharmacokinetics interaction, could be used as ‘maintenance’ antiretroviral therapy. We report a case report about one HIV-infected patient, on HAART and with a persistent suppression of HIV RNA, switched to dolutegravir 50 mg three times weekly plus atazanavir 400 mg once daily, as ‘maintenance antiretroviral therapy’, with persistence of viral suppression.
AB - Highly active antiretroviral therapy (HAART) has changed the natural course of HIV infection. However, the toxicities associated with long-term use of nucleoside reverse transcriptase inhibitors (NRTIs) have led to the assessment of dual-therapy approaches with less toxicity. Atazanavir and dolutegravir have antiviral potency, tolerability and favourable metabolic profile. In suppressed HIV-infected patients, with NRTIs-related toxicity effects, the association of atazanavir and dolutegravir, favoured by their positive pharmacokinetics interaction, could be used as ‘maintenance’ antiretroviral therapy. We report a case report about one HIV-infected patient, on HAART and with a persistent suppression of HIV RNA, switched to dolutegravir 50 mg three times weekly plus atazanavir 400 mg once daily, as ‘maintenance antiretroviral therapy’, with persistence of viral suppression.
KW - Atazanavir
KW - dolutegravir
KW - maintenance antiretroviral therapy
KW - pharmacokinetics
UR - http://www.scopus.com/inward/record.url?scp=85019020470&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019020470&partnerID=8YFLogxK
U2 - 10.1177/0956462416678164
DO - 10.1177/0956462416678164
M3 - Article
VL - 28
SP - 726
EP - 728
JO - International Journal of STD and AIDS
JF - International Journal of STD and AIDS
SN - 0956-4624
IS - 7
ER -